What question did this study set out to answer?

This analysis aims to assess the effects of olanzapine on lipid profiles in humans, focusing on dosage and timing.

January 10, 2026BMC Cardiovascular Disorders0 citationsOpen Access

The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials

Q: What does this research mean for the field?

Olanzapine treatment increases triglycerides, total cholesterol, and LDL-C while reducing HDL-C, particularly at higher doses and during early treatment. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

FZFang Zhou PJParmida Jamilian MSMohammad Safargar

Key Result

Olanzapine treatment increased triglycerides, total cholesterol, and LDL-C while reducing HDL-C, particularly at higher doses and early treatment.

Key Points

This analysis aims to assess the effects of olanzapine on lipid profiles in humans, focusing on dosage and timing.
Conducted a meta-analysis of randomized controlled trials
Evaluated lipid profile changes such as TG, TC, LDL-C, and HDL-C
Analyzed different dosages and treatment durations
Increased triglycerides (TG) and total cholesterol (TC) observed with olanzapine
Higher doses of olanzapine correspond with increased LDL-C levels
Reduced HDL-C noted, highlighting dyslipidemic profile during treatment

Structured PICO

Does olanzapine alter lipid profiles (TG, TC, HDL-C, LDL-C) in humans?

Population

17 RCTs pooling 2,124 participants (ranging from 14 to 308 per trial), including healthy volunteers, pediatric cancer patients, and individuals with psychiatric disorders (schizophrenia, bipolar I disorder, borderline personality disorder). Mean age ranged from 8.5 to 55 years, baseline BMI 18.5-25.4 kg/m2. Multinational (USA, Canada, China, Iran, Japan, India).

Intervention

Olanzapine at daily doses ranging from 4.83 mg/day to 17.5 mg/day, administered for durations ranging from 3 days to 36 weeks.

Comparator

Placebo

Outcome

Changes in lipid profiles (triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) before and after olanzapine treatment.surrogate

Olanzapine treatment causes significant dose- and time-dependent worsening of lipid profiles (increased TG, TC, LDL-C), highlighting the need for proactive lipid monitoring and cardiovascular risk assessment.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Olanzapine treatment is associated with a distinct dyslipidemic profile, characterized by increased TG, TC, and LDL-C and reduced HDL-C, particularly at higher doses and during early treatment. These findings underscore the need for proactive lipid monitoring and cardiovascular risk assessment, especially in patients with low baseline BMI, who appear more susceptible to rapid lipid alterations, and in those with existing metabolic risk factors or multiple cardiometabolic comorbidities.

问 AI

Bookmark

View Full Paper